Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nanoigel benzimidazole I2 receptor agonists
- Development stage
- Preclinical
- Lead developer
- nanoigel
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Nanoigel is developing a series of small molecule benzimidazole derivatives that act as agonists of the imidazoline I2 receptor. These compounds are being investigated for their potential as geroprotectors to treat aging and age-related pathologies, as well as for indications such as arterial hypertension and hypoglycemia. The imidazoline I2 receptors are primarily located in the central nervous system and peripheral tissues, and their modulation is associated with neuroprotection and metabolic regulation. The program is currently in the preclinical stage, with research supported by patent WO2021145785A1, which describes the synthesis and biological activity of these derivatives in enhancing lifespan and treating metabolic disorders.
- Other names
- benzimidazole derivativesimidazoline I2 receptor agonists
02
Targets
I2R (Imidazoline I2 receptor)
Beyond the preview
Go deeper on nanoigel benzimidazole I2 receptor agonists.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nanoigel benzimidazole I2 receptor agonists.